Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls

• Published in: Experimental neurobiology Vol. 34; no. 1; pp. 1 - 8
• Main Authors: Baek, Seungyeop, Lee, Jinny Claire, Byun, Byung Hyun, Park, Su Yeon, Ha, Jeong Ho, Lee, Kyo Chul, Yang, Seung-Hoon, Lee, Jun-Seok, Hong, Seungpyo, Han, Gyoonhee, Lim, Sang Moo, Kim, YoungSoo, Kim, Hye Yun
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society for Brain and Neural Sciences 28.02.2025; 한국뇌신경과학회
• Subjects: Short Communication; 뇌과학; Plasma; Tau; Amyloid; Alzheimer disease; Blood; Enzyme-linked immunosorbent assay
• ISSN: 1226-2560; 2093-8144
• DOI: 10.5607/en25008

Alzheimer disease (AD) diagnosis is confirmed using a medley of modalities, such as the detection of amyloid-β (Aβ) neuritic plaques and neurofibrillary tangles with positron electron tomography (PET) or the appraisal of irregularities in cognitive function with examinations. Although these methods have been efficient in confirming AD pathology, the rising demand for earlier intervention during pathogenesis has led researchers to explore the diagnostic potential of fluid biomarkers in cerebrospinal fluid (CSF) and plasma. Since CSF sample collection is invasive and limited in quantity, biomarker detection in plasma has become more attractive and modern advancements in technology has permitted more efficient and accurate analysis of plasma biomolecules. In this study, we found that a composite of standard factors, Aβ40 and total tau levels in plasma, divided by the variation factor, plasma Aβ42 level, provide better correlation with amyloid neuroimaging and neuropsychological test results than a level comparison between total tau and Aβ42 in plasma. We collected EDTA-treated blood plasma samples of 53 subjects, of randomly selected 27 AD patients and 26 normal cognition (NC) individuals, who received amyloid-PET scans for plaque quantification, and measured plasma levels of Aβ40, Aβ42, and total tau with digital enzyme-linked immunosorbent assay (ELISA) in a blinded manner. There was difficulty distinguishing AD patients from controls when analyzing biomarkers independently. However, significant differentiation was observed between the two groups when comparing individual ratios of total-tau×Aβ40/Aβ42. Our results indicate that collectively comparing fluctuations of these fluid biomarkers could aid in monitoring AD pathogenesis.